Peripheral nerve and brain differ in their capacity to resolve N,N-diethyldithiocarbamate-mediated elevations in copper and oxidative injury.
Previous studies have demonstrated that N,N-diethyldithiocarbamate (DEDC) elevates copper and promotes oxidative stress within the nervous system. However, whether these effects resolve following cessation of exposure or have the potential to persist and result in cumulative injury has not been determined. In this study, an established model for DEDC myelin injury in the rat was used to determine whether copper levels, oxidative stress, and neuromuscular deficits resolve following the cessation of DEDC exposure. Rats were exposed to DEDC for 8 weeks and then either euthanized or maintained for 2, 6 or 12 weeks after cessation of exposure. At each time point copper levels were measured by inductively coupled mass spectrometry to assess the ability of sciatic nerve, brain, spinal cord and liver to eliminate excess copper post-exposure. The protein expression levels of glutathione transferase alpha, heme oxygenase 1 and superoxide dismutase 1 in peripheral nerve and brain were also determined by western blot to assess levels of oxidative stress as a function of post-exposure duration. As an initial assessment of the bioavailability of the excess copper in brain the protein expression levels of copper chaperone for superoxide dismutase 1, and prion protein were determined by western blot as a function of exposure and post-exposure duration. Neuromuscular function in peripheral nerve was evaluated using grip strengths, nerve conduction velocities, and morphologic changes at the light microscope level. The data demonstrated that in peripheral nerve, copper levels and oxidative stress return to control levels within several weeks after cessation of exposure. Neuromuscular function also showed a trend towards pre-exposure values, although the resolution of myelin lesions was more delayed. In contrast, total copper and antioxidant enzyme levels remained significantly elevated in brain for longer post-exposure periods. The persistence of effects observed in brain suggests that the central nervous system is more susceptible to long-term cumulative adverse effects from dithiocarbamates. Additionally, significant changes in expression levels of chaperone for superoxide dismutase 1, and prion protein were observed consistent with at least a portion of the excess copper being bioactive.
Valentine
Holly L
HL
Department of Pathology, Vanderbilt University Medical Center, 1161 21st Ave. S., Nashville, TN 37232-2561, USA.
Viquez
Olga M
OM
Valentine
William M
WM
D000818:Animals; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D003300:Copper / Q000378:metabolism* / Q000494:pharmacology; D004050:Ditiocarb / Q000378:metabolism / Q000494:pharmacology; D005982:Glutathione Transferase / Q000378:metabolism / Q000494:pharmacology; D051547:Heme Oxygenase-1 / Q000378:metabolism / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D009186:Myelin Sheath / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013116:Spinal Cord / Q000378:metabolism; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1
D003300:Copper; D004050:Ditiocarb; D051547:Heme Oxygenase-1; C000606292:Sod1 protein, rat; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D005982:Glutathione Transferase
Teratog Carcinog Mutagen. 1995-1996;15(6):313-37
8732882
Methods Enzymol. 2005;401:379-407
16399399
Acta Pharmacol Toxicol (Copenh). 1979 Jul;45(1):41-4
224644
Nutr J. 2005 Nov 24;4:35
16307684
Annu Rev Pharmacol Toxicol. 2003;43:233-60
12359864
J Neurosci Res. 2000 Jan 1;59(1):47-62
10658185
Exp Biol Med (Maywood). 2004 Sep;229(8):756-64
15337829
Toxicol Appl Pharmacol. 2003 Jun 1;189(2):139-50
12781632
Br J Nutr. 2007 Oct;98(4):676-83
17666147
Toxicol Sci. 2006 Feb;89(2):485-94
16291825
Annu Rev Pharmacol Toxicol. 1981;21:575-96
7016017
Drug Metab Rev. 1979;9(2):319-35
385275
Toxicol Appl Pharmacol. 2008 May 15;229(1):77-85
18284930
Cell Mol Life Sci. 2009 Dec;66(23):3809-20
19756378
J Comp Pathol. 1999 Jan;120(1):29-37
10098014
J Neuropathol Exp Neurol. 2000 Sep;59(9):786-97
11005259
Arch Biochem Biophys. 2003 Sep 15;417(2):227-34
12941305
Methods Mol Biol. 1999;112:99-103
10027233
FEBS Lett. 2005 Jan 31;579(3):741-4
15670838
Toxicol Appl Pharmacol. 2009 Aug 15;239(1):71-9
19467251
FASEB J. 1996 Aug;10(10):1129-36
8751715
Chem Res Toxicol. 2009 Jan;22(1):218-26
19093748
Toxicol Lett. 2005 Jul 28;158(1):61-71
15993744
Anal Biochem. 1994 Sep;221(2):243-9
7810863
Genes Nutr. 2006 Mar;1(1):51-9
18850220
Toxicol Sci. 2004 Sep;81(1):160-71
15187237